Member Info for shatter

Yep, as a lth I am also in the “hold and hope” camp ! This is still a very volatile share and moves for little or no reason and small volume. Will be very off putting for possible new investors here. Oxb have bandied about huge figures over the years in various rns’s which are still pie in the sky at the moment but it is moving forward. 14p in old money so not to bad but not sure when we will see the 20’s again?

Kontiti were either very lucky or had pre-knowledge of this huge sale.....hmmmm?

The shorters seem to be at odds with themselves. Hopefully the May results will put a nail in their coffin and we can move forward.

Up to 758 and down to 711 and up a bit....bumpy ride. Hate being right . Hehe .

Must be due a drop soon ....hehe

Hardman & Co: Deal-making drives first annual profit

OXB is a specialist, advanced therapy, viral-vector biopharmaceutical company. It offers vector manufacturing and development services, while developing proprietary drug candidates. OXB also receives royalties on commercial products developed with its LentiVector(R) platform. 2018 delivered significant growth in gross income, primarily through licensing income from new partnership deals with Axovant Sciences (AXON) and Bioverativ (BIVV). Licensing income was of a magnitude that delivered OXB's first full-year underlying operating profit, despite weaker-than-anticipated bioprocessing/commercial sales and investment to increase capacity.

Making progress finally.. good news !

Never thought anyone would reply to my moaning !

Must be due some manufacturing woes soon or another fund raising!

Let’s hope so.. another 19p and I have broken even...it’s been a long hold but looking a lot brighter now

Just the market today.... disaster all round

Showing my age.. you just couldn’t write this. I removed this debacle from my portfolio some months ago after watching my investment dwindle to a pittance. Perhaps a pessimist by nature but I said this was a write-off a couple of years ago but a NURSERY ?

Jefferies reiterates hold with a target price of 725p

Wish I could say that the sp is rising on the back of the results but Oxb is up and down like a fiddlers elbow

Moving on very low volume but welcome nevertheless.

Borrowed from Advfn. “ It is going to be another year before we can grow our income through our normal business of manufacturing.If, at capacity, we make 45m in revenue (69 less 18 from Axovant and bioverativ and 6 from OTP share value increase) and our operating costs are 54m then without further milestones we are not making a profit.On top of that we have a 40m loan which is costing us 6m to service (15%!!) ..and it's still growing!I
Cashburn is still a massive concern.

If it wasn’t for the one off £22 million from Axovant Sciences and the fundraising results would look fairly grim. Let’s hope Axovant are successful. Even today volume is tiny... what about a big fat divi - that might help ;-)

Have to agree... can see a further fundraising later this year.

Cop out...this is still in the development phase. If it gets approval then it’s transformational. Fingers crossed.

Market not impressed ! They keep mentioning £842 million as if it’s a done deal ... only entering phase 2 now. Very high cash burn with a lot of wages to pay. This time next year, eh?